In the phase III MAGELLAN ( Multicenter , rAndomized , parallel Group Efficacy and safety study for the prevention of venous thromboembolism in hospitalized medically iLL patients comparing rivaroxabAN with enoxaparin ) trial , extended-duration rivaroxaban was compared with standard-duration enoxaparin followed by placebo for VTE prevention in @ hospitalized acutely ill patients with or without HF .